Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia

Trial Profile

Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Sirolimus (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2018 Planned End Date changed from 31 Jan 2018 to 31 Jan 2019.
    • 07 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 31 Jan 2019.
    • 08 Jul 2017 Planned number of patients changed from 124 to 150.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top